volixibat (SAR 548304) / Mirum Pharma 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   50 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
volixibat (SAR 548304) / Mirum Pharma
2020-003027-41: A study to evaluate efficacy and safety of an investigational drug named volixibat in patients with itching caused by primary sclerosing cholangitis

Not yet recruiting
2
300
Europe
Volixibat (formely SHP626, LUM002 or SAR548304B), Capsule, hard
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Pruritus associated with Primary Sclerosing Cholangitis (PSC), Itching in patients with primary sclerosing cholangitis, Diseases [C] - Digestive System Diseases [C06]
 
 
2021-001389-39: A study to evaluate efficacy and safety of an investigational drug named volixibat in patients with itching caused by primary biliary cholangitis

Not yet recruiting
2
260
Europe
volixibat, [volixibat], Capsule, hard
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals Inc., Mirum Pharmaceuticals, Inc.
Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC), Itching in patients with Primary Biliary Cholangitis (PBC), Diseases [C] - Digestive System Diseases [C06]
 
 
OHANA, NCT04718961: A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy

Terminated
2
4
Europe, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc.
Intrahepatic Cholestasis of Pregnancy
12/22
12/22
VANTAGE, NCT05050136 / 2021-001389-39: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Recruiting
2
180
Europe, Canada, Japan, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Biliary Cholangitis, PBC
12/25
12/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
volixibat (SAR 548304) / Mirum Pharma
2020-003027-41: A study to evaluate efficacy and safety of an investigational drug named volixibat in patients with itching caused by primary sclerosing cholangitis

Not yet recruiting
2
300
Europe
Volixibat (formely SHP626, LUM002 or SAR548304B), Capsule, hard
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Pruritus associated with Primary Sclerosing Cholangitis (PSC), Itching in patients with primary sclerosing cholangitis, Diseases [C] - Digestive System Diseases [C06]
 
 
2021-001389-39: A study to evaluate efficacy and safety of an investigational drug named volixibat in patients with itching caused by primary biliary cholangitis

Not yet recruiting
2
260
Europe
volixibat, [volixibat], Capsule, hard
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals Inc., Mirum Pharmaceuticals, Inc.
Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC), Itching in patients with Primary Biliary Cholangitis (PBC), Diseases [C] - Digestive System Diseases [C06]
 
 
OHANA, NCT04718961: A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy

Terminated
2
4
Europe, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc.
Intrahepatic Cholestasis of Pregnancy
12/22
12/22
VANTAGE, NCT05050136 / 2021-001389-39: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Recruiting
2
180
Europe, Canada, Japan, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Biliary Cholangitis, PBC
12/25
12/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25

Download Options